Ken Griffin Fate Therapeutics Inc Put Options Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2024 Feb 14, 2025	BUY	$1.61 - $3.35 $11,109 - $23,115	6,900 Added 76.67%	15,900 $26,000
Q3 2024 Nov 14, 2024	SELL	$3.12 - $5.57 $15,600 - $27,850	-5,000 Reduced 35.71%	9,000 $31,000
Q2 2024 Aug 14, 2024	BUY	$3.26 - $7.08 $14,343 - $31,152	4,400 Added 45.83%	14,000 $45,000
Q1 2024 May 15, 2024	SELL	$3.54 - $8.35 $4,248 - $10,020	-1,200 Reduced 11.11%	9,600 $70,000
Q4 2023 Feb 14, 2024	BUY	$1.65 - $3.94 $3,300 - $7,880	2,000 Added 22.73%	10,800 $40,000
Q3 2023 Nov 14, 2023	SELL	$2.02 - $5.04 $27,472 - $68,544	-13,600 Reduced 60.71%	8,800 $18,000
Q2 2023 Aug 14, 2023	SELL	$4.76 - $6.59 $16,184 - $22,406	-3,400 Reduced 13.18%	22,400 $106,000
Q1 2023 May 15, 2023	SELL	$4.24 - $11.12 $19,504 - $51,152	-4,600 Reduced 15.13%	25,800 $147,000
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $173,536 - $419,407	17,600 Added 137.5%	30,400 $306,000
Q3 2022 Nov 14, 2022	SELL	$21.04 - $36.06 $2,104 - $3,606	-100 Reduced 0.78%	12,800 $287,000

167

108M

79.2K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $138M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.